市場調查報告書

按藥物,給藥途徑,區域大小,佔有率,前景和機會分析進行的骨發育不良治療市場(2020-2027)

Osteogenesis Imperfecta Treatment Market, by Drugs By Route of Administration, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 952877
出版日期 內容資訊 英文 150 Pages
商品交期: 2-3個工作天內
價格
按藥物,給藥途徑,區域大小,佔有率,前景和機會分析進行的骨發育不良治療市場(2020-2027) Osteogenesis Imperfecta Treatment Market, by Drugs By Route of Administration, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年08月05日內容資訊: 英文 150 Pages
簡介

骨質疏鬆症或OI是一種遺傳性疾病,會影響骨骼並阻止人體形成強壯的骨骼。 OI被稱為不完整的骨形成,患有這種疾病的人的骨骼斷裂而脆弱。因此,這種情況通常也稱為脆性骨病。在嚴重的OI病例中多發骨折很常見,但在少數情況下很少發生骨折或骨折。

用於研發新療法的研發資金激增是全球骨塑療法市場增長的主要動力。此外,為開發OI治療藥物,與領先的行業參與者簽訂許可協議和進行戰略合作是推動市場增長的另一個因素。例如,在2020年1月,Oncologie,Inc.與Mereo BioPharma Group plc簽署了開發和商業化Navicixizumab的許可協議。這是一種抗DLL4/VEGF雙特異性抗體,用於治療成骨不全症。

此外,成骨不全症是一種遺傳性疾病,OI患者的家族病史導致全球病例增加,這有望推動市場增長。例如,根據《遺傳學家庭參考》(GHR),全世界大約10,000至20,000人中有1人患有成骨不全症(OI)。

然而,缺乏訓練有素的專業人員和治療方法的缺乏是限制全球骨營養不良症治療市場增長的一些關鍵因素。

本報告調查了骨營養不良症治療市場,並概述了市場,市場增長因素和障礙因素的分析,按藥物/給藥途徑/地區,競爭狀況和主要公司分列的市場規模趨勢和預測。我們提供有關個人資料,Covid-19影響,市場機會等的系統信息。

目錄

第1章調查目的和假設

第2章市場概述

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
    • 市場細分:按藥品
    • 市場細分:按管理途徑劃分
    • 市場細分:按地區
  • 相干機會圖(COM)

第3章市場動態,法規,趨勢分析

  • 市場動態
    • 促進要因
    • 抑制因子
    • 市場機會
  • 影響分析
  • 成骨不全症治療的新進展
  • 管道分析
  • 主要發展
  • 收購,合作,夥伴關係
  • 流行病學

第4章冠狀病毒(Covid-19)的作用

  • COVID之前的情況
  • COVID後的需求
  • 需要治療成骨不全症
  • 建議和準則:監管機構

第5章,藥品:2016-2027年(百萬美元)

  • 簡介
  • 替拉帕□
  • Denosumab
  • 其他

第6章,按管理路線劃分:2016-2027(百萬美元單位)

  • 簡介
  • 皮下
  • 靜脈
  • 口服
  • 其他

第7章,按地區:2016-2027(百萬美元)

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 非洲
  • 中東

第8章競爭情況

  • 公司簡介
    • Bone Therapeutics SA
    • Mereo BioPharma Group plc
    • Celgene Corporation
    • Eli Lilly and Company
    • Cipla Inc.
    • Amgen Inc
    • Sun Pharmaceutical Industries Limited
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd
    • Merck & Co., Inc.
    • Jubilant Life Sciences Ltd.
    • Aurobindo Pharma
    • Genzyme Corp.

第9章Section

目錄

Osteogenesis imperfecta or OI is a genetic disorder that affects the bones and also prevents the body from building strong bones. OI is referred to as imperfect bone formation and people suffering from this disorder have bones that fracture or break easily. Therefore, this condition is also commonly known as brittle bone disease. In severe OI cases, multiple fractures are common, whereas a milder case involves few fractures or bone breaks in a person's lifetime.

Market Dynamics

The surge in funding for research and development to develop novel treatment and therapies is a major factor boosting growth of the global osteogenesis imperfecta treatment market. Moreover, licensing agreements and strategic collaborations by key industry players for the development of OI treatment is another factor propelling the market growth. For instance, in January 2020, Oncologie, Inc. and Mereo BioPharma Group plc entered into a license agreement to develop and commercialize 'Navicixizumab.' It is an anti-DLL4/VEGF bi-specific antibody for osteogenesis imperfecta treatment.

Moreover, osteogenesis imperfecta is a genetic disorder and the family history of people with OI is resulting in rising number of cases across the globe, which is expected to drive the market growth. For instance, according to the Genetics Home Reference (GHR), osteogenesis imperfecta (OI) affects about 1 in 10,000 to 20,000 people across the globe.

However, the lack of trained professionals and non-availability of treatment are some of the major factors restraining growth of the global osteogenesis imperfecta treatment market.

Key features of the study:

  • This report provides in-depth analysis of the global osteogenesis imperfecta treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains the attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global osteogenesis imperfecta treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
  • Key players covered as a part of this study are Genzyme Corp., Bone Therapeutics SA, Sun Pharmaceutical Industries Limited, Mereo BioPharma Group plc, Mylan N.V., Celgene Corporation, Amgen Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Cipla Inc., Merck & Co., Inc. Aurobindo Pharma, and Jubilant Life Sciences Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global osteogenesis imperfecta treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for osteogenesis imperfecta treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Detailed Segmentation:

  • Global Osteogenesis Imperfecta Treatment Market, By Drugs:
    • Teriparatide
    • Denosumab
    • Others
  • Global Osteogenesis Imperfecta Treatment Market, By Route of Administration:
    • Subcutaneous
    • Intravenous
    • Oral
    • Others
  • Global Osteogenesis Imperfecta Treatment Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Drugs:
    • Teriparatide
    • Denosumab
    • Others
      • By Route of Administration:
    • Subcutaneous
    • Intravenous
    • Oral
    • Others
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Drugs:
    • Teriparatide
    • Denosumab
    • Others
      • By Route of Administration:
    • Subcutaneous
    • Intravenous
    • Oral
    • Others
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Drugs:
    • Teriparatide
    • Denosumab
    • Others
      • By Route of Administration:
    • Subcutaneous
    • Intravenous
    • Oral
    • Others
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Drugs:
    • Teriparatide
    • Denosumab
    • Others
      • By Route of Administration:
    • Subcutaneous
    • Intravenous
    • Oral
    • Others
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Drugs:
    • Teriparatide
    • Denosumab
    • Others
      • By Route of Administration:
    • Subcutaneous
    • Intravenous
    • Oral
    • Others
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
      • By Drugs:
    • Teriparatide
    • Denosumab
    • Others
      • By Route of Administration:
    • Subcutaneous
    • Intravenous
    • Oral
    • Others
  • Company Profiles
    • Genzyme Corp.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Bone Therapeutics SA
    • Sun Pharmaceutical Industries Limited
    • Mereo BioPharma Group plc
    • Mylan N.V.
    • Celgene Corporation
    • Amgen Inc
    • Eli Lilly and Company
    • Teva Pharmaceutical Industries Ltd
    • Cipla Inc.
    • Merck & Co., Inc.
    • Aurobindo Pharma
    • Jubilant Life Sciences Ltd.
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drugs
    • Market Snippet, By Route of Administration
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • New Development in Osteogenesis Imperfecta Treatment
  • Pipeline Analysis
  • Key Developments
  • Acquisition, Collaborations & Partnerships
  • Epidemiology

4. Global Osteogenesis Imperfecta Treatment Market, Impact of Coronavirus (Covid-19) Pandemic

  • Pre-COVID situation
  • Post-COVID demand
  • Need for Osteogenesis Imperfecta Treatment
  • Recommendations and Guidelines by Regulatory Bodies

5. Global Osteogenesis Imperfecta Treatment Market, By Drugs, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Teriparatide
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Denosumab
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Osteogenesis Imperfecta Treatment Market, By Route of Administration, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Subcutaneous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Osteogenesis Imperfecta Treatment Market, By Region, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027(%)
    • Y-o-Y Growth Analysis, By Region, 2017 -2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drugs, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drugs, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drugs, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drugs, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drugs, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drugs, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • Bone Therapeutics SA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Mereo BioPharma Group plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Celgene Corporation
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Cipla Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Amgen Inc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sun Pharmaceutical Industries Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Mylan N.V.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Jubilant Life Sciences Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Aurobindo Pharma
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Genzyme Corp.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

9. Section

  • References
  • Research Methodology
  • About Us us and Sales Contact